Drugdocs | Braftovi

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Braftovi

Chemical Name	encorafenib
Dosage Form	Capsule (oral; 75 mg)
Drug Class	Kinase inhibitors
System	Skin
Company	Array Biopharma
Approval Year	2018

Indication

Braftovi is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

Last updated on 10/19/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Braftovi (encorafenib) Prescribing Information	2019	Array Biopharma

Document Title	Year	Source
Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma.	2019	NICE

Document Title	Year	Source
Efficacy and adverse events in metastatic melanoma patients treated with combination BRAF plus MEK inhibitors versus BRAF Inhibitors: a systematic review.	2019	Cancers (Basel)

Document Title	Year	Source
Systemic therapy for melanoma: ASCO guideline.	2020	American Society of Clinical Oncology